Foghorn Therapeutics
Kevin Wilson joined Foghorn in 2019 as director in medicinal chemistry and now serves as VP, Head of Chemistry. He brings more than 20 years of drug discovery experience to the organization.
Before joining Foghorn, Kevin was at Blueprint Medicines where he was the chemistry lead for numerous kinase inhibitor programs within oncology. Prior to that, he began his drug discovery career at Merck, initially within their Neuroscience Research Centre in the UK before transitioning to the Boston, the US to focus on various target classes within oncology and immunology. Kevin is a named inventor on more than 30 patent applications, and he contributed to the discovery of approved kinase therapies AYVAKIT® and GAVRETO®, and investigational mutant EGFR inhibitor undergoing clinical evaluation.
Kevin received an MSci honors degree in chemistry from Durham University, UK. His research project focused on the reactivity of fluorinated alkenes.
This person is not in any offices
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.